New insights in the pathology of peritoneal surface malignancy
- PMID: 33968439
- PMCID: PMC8100698
- DOI: 10.21037/jgo-2020-01
New insights in the pathology of peritoneal surface malignancy
Abstract
Pathology is central to the management of peritoneal surface malignancy. This article highlights some recent advances that have had an impact on patient management or could do so in the near future. Malignant peritoneal mesothelioma, particularly the epithelioid subtype, is amenable to radical therapy in selected cases, and factors such as ki67 proliferation index, expression of BAP1 and mutation in CDKN2A show promise as prognostic indicators. Our understanding of multicystic mesothelioma has improved in recent years; it is a true neoplasm for which surgery may be indicated. Serous carcinomas involving the peritoneum are now known to originate from tubal epithelium. They are of two distinct types, high grade and low grade, which are now recognized as different neoplasms with distinctive features, oncogenesis and behavior. Pseudomyxoma peritonei (PMP) is an unusual condition that usually arises from an appendiceal mucinous neoplasm. Recent consensus in the classification and nomenclature of these lesions is discussed, including the distinction between low grade and high grade appendiceal mucinous neoplasms (HAMN), and the diagnostic criteria for appendiceal adenocarcinoma. PMP is divided into four prognostic groups: acellular mucin, low grade mucinous carcinoma peritonei, high grade mucinous carcinoma peritonei, and high grade mucinous carcinoma peritonei with signet ring cells. The pseudomyxoma microbiome is a promising area for clinical intervention but has been the subject of little research activity. Goblet cell adenocarcinoma (previously known as 'goblet cell carcinoid') is a distinctive type of appendiceal adenocarcinoma. Its behavior correlates with histologic features, but no general consensus for classification has been reached.
Keywords: Appendiceal neoplasms; mesothelioma; peritoneal neoplasms; pseudomyxoma peritonei (PMP); serous carcinoma.
2021 Journal of Gastrointestinal Oncology. All rights reserved.
Conflict of interest statement
Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jgo-2020-01). The focused issue was sponsored by the Peritoneal Surface Oncology Group International (PSOGI). The author has no other conflicts of interest to declare.
Figures
Comment in
-
A model for accurate histopathologic assessment refines treatment options.J Gastrointest Oncol. 2021 Apr;12(Suppl 1):S230. doi: 10.21037/jgo-2020-20. J Gastrointest Oncol. 2021. PMID: 33970168 Free PMC article. No abstract available.
References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous